Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | MMEL1 | Q495T6 | 4/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231435 | 1.00 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231592 | 1.00 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL12888104 | 1.00 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL12888110 | 0.91 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL21572792 | 0.91 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1232158 | 0.91 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL18576747 | 0.91 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231410 | 0.91 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL597498 | 0.91 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1908521 | 0.91 | MME (0.54) | MMEACEMMEL1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245009-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-20140243546-A1 | Processes | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20140243546-A1 | Processes | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8580974-B2 | Processes | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580974-B2 | Processes | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580974-B2 | Processes | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| EP-2245009-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009090251-A2 | NEW PROCESSES | NOVARTIS AG (CH) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060217-A1 | Processes | MME, NAT1, AGTR1 | MME 1/4885ACE 6/4885MMEL1 69/4885 |
| US-20110046397-A1 | NEW PROCESSES | MME, REN, AGTR1 | MME 1/4885ACE 6/4885MMEL1 90/4885 |
| US-20140243546-A1 | Processes | MME, NAT1, AGTR1 | MME 1/4885ACE 6/4885MMEL1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.